Navigation Links
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Date:1/15/2009

IRVINE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced that ISTA's New Drug Application (NDA) for Bepreve(TM) (bepotastine ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA). The Company is seeking approval for Bepreve as an eye drop treatment for ocular itching associated with allergic conjunctivitis. The Company expects a standard review of ten months and has been given a user fee action date of September 12, 2009.

ISTA's Phase III clinical studies with Bepreve demonstrated highly statistically significant reductions in the primary endpoints of ocular itching. In addition, the results showed Bepreve had a statistically significant effect on the rapidity of response and on additional signs or symptoms of ocular allergy, including improvement in nasal symptoms. There were no serious ocular adverse events reported in patients dosed with Bepreve.

About Bepreve(TM) (bepotastine ophthalmic solution)

Assuming approval from the FDA, Bepreve would participate in ISTA's largest market to date. IMS Health estimates the U.S. ocular allergy market generated approximately $560 million in sales in 2007. Bepreve is a non-sedating, highly selective antagonist of the histamine (H1) receptor. It has a stabilizing effect on mast cells and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against the signs and symptoms of allergic conjunctivitis.

Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the b
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 23D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... Ga., April 16, 2012  GeckoSystems Intl. Corp. (Pink ... ) -- is closely reviewing the scope and ... wheelchair technology. As a result of recent enhancements ... suite of fundamental mobile robot solutions for automatic, ...
... 16, 2012  Morphotek®, Inc., a subsidiary of Eisai Inc., ... II study evaluating the safety and efficacy of MORAb-004 ... refractory to all standard therapy. MORAb-004 is a monoclonal ... The trial is a randomized, double-blind, ...
Cached Medicine Technology:GeckoSystems Evaluates Europe's Robotic Wheelchair Market 2GeckoSystems Evaluates Europe's Robotic Wheelchair Market 3GeckoSystems Evaluates Europe's Robotic Wheelchair Market 4GeckoSystems Evaluates Europe's Robotic Wheelchair Market 5GeckoSystems Evaluates Europe's Robotic Wheelchair Market 6Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 3
(Date:7/31/2015)... York, New York (PRWEB) , ... July 31, 2015 , ... ... to strut their stuff, Super-Sod debuted their new type of sod called Leisure ... registered trademark application in process. , To commemorate introduction of this new type of ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... new industry players to know in predictive health analytics , Jvion continues ... technologies. The firm creates predictive software that targets patient and population level illness ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug ... new True North Conference Center. The medical community, social workers, law enforcement, and ... be more aligned in the effort to better understand and combat sex trafficking. ...
(Date:7/31/2015)... ... ... According to the article published July 27 on My News LA, a fire ... by the city’s fire department before it caused major damage throughout the building. The article ... and it was a fire alarm system that tipped off fire fighters so they could ...
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 , ... ... Pet Sitter believes community involvement and support of animal welfare organizations is essential to ... for the third consecutive year in the National Association of Professional Pet Sitters (NAPPS) ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4
... revealed that women diagnosed with breast cancer should either ... then they should continue exercising, for it will help ... researchers analysed 500 women, who had survived breast cancer, ... the intensity and amount of physical activity before and ...
... A recent study has found that vegetarian diet reduces risk ... that fatty soup as appetizer reduces food intake by about ... factors like choosing your diet regimen or ordering an appetizer ... ,Researchers from Tata Memorial Hospital (TMH) in Mumbai, India, ...
... condition that most people prefer not to talk about, yet ... embarrassing problem. It's called overactive bladder (OAB) and it's ... causing urine leakage. ,Now, to reduce the symptoms ... nerve stimulation in the ankle to better help control the ...
... researchers at Imperial College London refutes the long-standing "runaway" theory ... fight infection by attacking T helper cells, a class of ... ,Scientists have for long been puzzled as to why this ... decade or more. ,According to the "runaway" hypothesis, ...
... made to recover two missing radiation detectors in the ... of Asia's biggest rivers, a Japanese filmmaker has warned. ... Times who now runs an independent documentary-making agency, is ... to mobilise search and recovery operations on the slopes ...
... study has found that apart from using mobile phones while ... vehicle could increase the risk of a crash. ... intended to determine the danger of a crash related with ... while driving. ,And the researchers found that passengers ...
Cached Medicine News:Health News:Exercise may Help Breast Cancer Patients to Lead a Healthy Life 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 3Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 4Health News:Stimulating the Ankle Can Help Patients With Overactive Bladder 2Health News:Study Refutes Theory on HIV's Effect on White Blood Cells 2Health News:Are Main Rivers in Himalayas Under Threat? 2Health News:Are Main Rivers in Himalayas Under Threat? 3Health News:Not Only Mobile Phones, Even Passengers can Increase the Risk of Road Accidents 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: